{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T00:48:40Z","timestamp":1794012520187,"version":"4.8.0"},"reference-count":365,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1038\/s41568-026-00958-4","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T11:08:56Z","timestamp":1785236936000},"page":"713-736","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The DNA damage response and cancer immunotherapy"],"prefix":"10.1038","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0113-9958","authenticated-orcid":false,"given":"Sheng","family":"Hong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9842-4578","authenticated-orcid":false,"given":"Guo-Min","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"key":"958_CR1","doi-asserted-by":"crossref","unstructured":"Friedberg, E. C. et al. DNA Repair and Mutagenesis (ASM Press, 2006).","DOI":"10.1128\/9781555816704"},{"key":"958_CR2","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/cr.2007.115","volume":"18","author":"GM Li","year":"2008","unstructured":"Li, G. M. Mechanisms and functions of DNA mismatch repair. Cell Res. 18, 85\u201398 (2008).","journal-title":"Cell Res."},{"key":"958_CR3","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.tibs.2023.11.001","volume":"49","author":"KW Caldecott","year":"2024","unstructured":"Caldecott, K. W. Causes and consequences of DNA single-strand breaks. Trends Biochemical Sci. 49, 68\u201378 (2024).","journal-title":"Trends Biochemical Sci."},{"key":"958_CR4","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.molcel.2010.09.019","volume":"40","author":"A Ciccia","year":"2010","unstructured":"Ciccia, A. & Elledge, S. J. The DNA damage response: making it safe to play with knives. Mol. Cell 40, 179\u2013204 (2010).","journal-title":"Mol. Cell"},{"key":"958_CR5","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ccell.2020.11.004","volume":"39","author":"JH Guan","year":"2021","unstructured":"Guan, J. H. et al. MLH1 deficiency-triggered DNA hyperexcision by exonuclease 1 activates the cGAS\u2013STING pathway. Cancer Cell 39, 109\u2013121 (2021).","journal-title":"Cancer Cell"},{"key":"958_CR6","doi-asserted-by":"publisher","first-page":"a012716","DOI":"10.1101\/cshperspect.a012716","volume":"5","author":"A Marechal","year":"2013","unstructured":"Marechal, A. & Zou, L. DNA damage sensing by the ATM and ATR kinases. Cold Spring Harb. Perspect. Biol. 5, a012716 (2013).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"958_CR7","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1146\/annurev.genet.34.1.479","volume":"34","author":"MD Sutton","year":"2000","unstructured":"Sutton, M. D., Smith, B. T., Godoy, V. G. & Walker, G. C. The SOS response: recent insights into umuDC-dependent mutagenesis and DNA damage tolerance. Annu. Rev. Genet. 34, 479\u2013497 (2000).","journal-title":"Annu. Rev. Genet."},{"key":"958_CR8","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.dnarep.2009.04.012","volume":"8","author":"TH Stracker","year":"2009","unstructured":"Stracker, T. H., Usui, T. & Petrini, J. H. Taking the time to make important decisions: the checkpoint effector kinases Chk1 and Chk2 and the DNA damage response. DNA Repair\u00a08, 1047\u20131054 (2009).","journal-title":"DNA Repair"},{"key":"958_CR9","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/nrc3063","volume":"11","author":"LA Loeb","year":"2011","unstructured":"Loeb, L. A. Human cancers express mutator phenotypes: origin, consequences and targeting. Nat. Rev. Cancer 11, 450\u2013457 (2011).","journal-title":"Nat. Rev. Cancer"},{"key":"958_CR10","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646\u2013674 (2011).","journal-title":"Cell"},{"key":"958_CR11","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1146\/annurev.immunol.19.1.565","volume":"19","author":"CA Chambers","year":"2001","unstructured":"Chambers, C. A., Kuhns, M. S., Egen, J. G. & Allison, J. P. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu. Rev. Immunol. 19, 565\u2013594 (2001).","journal-title":"Annu. Rev. Immunol."},{"key":"958_CR12","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/joim.12708","volume":"283","author":"PS Chowdhury","year":"2018","unstructured":"Chowdhury, P. S., Chamoto, K. & Honjo, T. Combination therapy strategies for improving PD-1 blockade efficacy: a new era in cancer immunotherapy. J. Intern. Med. 283, 110\u2013120 (2018).","journal-title":"J. Intern. Med."},{"key":"958_CR13","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1126\/science.aaf1490","volume":"351","author":"N McGranahan","year":"2016","unstructured":"McGranahan, N. et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351, 1463\u20131469 (2016).","journal-title":"Science"},{"key":"958_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-023-00442-4","volume":"7","author":"D Wang","year":"2023","unstructured":"Wang, D. et al. Relationship among DDR gene mutations, TMB and PD-L1 in solid tumour genomes identified using clinically actionable biomarker assays. NPJ Precis. Oncol. 7, 103 (2023).","journal-title":"NPJ Precis. Oncol."},{"key":"958_CR15","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.immuni.2014.10.017","volume":"41","author":"SR Woo","year":"2014","unstructured":"Woo, S. R. et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 41, 830\u2013842 (2014).","journal-title":"Immunity"},{"key":"958_CR16","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","volume":"357","author":"DT Le","year":"2017","unstructured":"Le, D. T. et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357, 409\u2013413 (2017). This landmark study establishes that MMR deficiency is a pan-cancer biomarker for ICI response, independent of tumour origin.","journal-title":"Science"},{"key":"958_CR17","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le, D. T. et al. PD-1 Blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509\u20132520 (2015). This practice-changing phase II trial first demonstrates that pembrolizumab achieves durable responses in MMR-deficient cancers, leading to the first tissue-agnostic FDA approval.","journal-title":"N. Engl. J. Med."},{"key":"958_CR18","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.aaa4971","volume":"348","author":"TN Schumacher","year":"2015","unstructured":"Schumacher, T. N. & Schreiber, R. D. Neoantigens in cancer immunotherapy. Science 348, 69\u201374 (2015).","journal-title":"Science"},{"key":"958_CR19","doi-asserted-by":"publisher","first-page":"17101","DOI":"10.1073\/pnas.0907147106","volume":"106","author":"TM Albertson","year":"2009","unstructured":"Albertson, T. M. et al. DNA polymerase \u03b5 and \u03b4 proofreading suppress discrete mutator and cancer phenotypes in mice. Proc. Natl Acad. Sci. USA 106, 17101\u201317104 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"958_CR20","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1001\/jamaoncol.2015.2151","volume":"1","author":"BE Howitt","year":"2015","unstructured":"Howitt, B. E. et al. Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1. JAMA Oncol. 1, 1319\u20131323 (2015).","journal-title":"JAMA Oncol."},{"key":"958_CR21","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ccell.2020.11.006","volume":"39","author":"C Lu","year":"2021","unstructured":"Lu, C. et al. DNA sensing in mismatch repair-deficient tumor cells is essential for anti-tumor immunity. Cancer Cell 39, 96\u2013108.e6 (2021).","journal-title":"Cancer Cell"},{"key":"958_CR22","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41573-024-01060-w","volume":"24","author":"Y Drew","year":"2025","unstructured":"Drew, Y., Zenke, F. T. & Curtin, N. J. DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications. Nat. Rev. Drug Discov. 24, 19\u201339 (2025).","journal-title":"Nat. Rev. Drug Discov."},{"key":"958_CR23","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1158\/2159-8290.CD-22-1220","volume":"13","author":"V Klapp","year":"2023","unstructured":"Klapp, V. et al. The DNA damage response and inflammation in cancer. Cancer Discov. 13, 1521\u20131545 (2023).","journal-title":"Cancer Discov."},{"key":"958_CR24","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/s41571-024-00863-5","volume":"21","author":"NYL Ngoi","year":"2024","unstructured":"Ngoi, N. Y. L. et al. Targeting ATR in patients with cancer. Nat. Rev. Clin. Oncol. 21, 278\u2013293 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"958_CR25","doi-asserted-by":"publisher","first-page":"100276","DOI":"10.1016\/j.xcrm.2021.100276","volume":"2","author":"T Qing","year":"2021","unstructured":"Qing, T. et al. Diverse immune response of DNA damage repair-deficient tumors. Cell Rep. Med. 2, 100276 (2021).","journal-title":"Cell Rep. Med."},{"key":"958_CR26","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1101\/gr.246223.118","volume":"29","author":"M Jager","year":"2019","unstructured":"Jager, M. et al. Deficiency of nucleotide excision repair is associated with mutational signature observed in cancer. Genome Res. 29, 1067\u20131077 (2019).","journal-title":"Genome Res."},{"key":"958_CR27","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/ng.3557","volume":"48","author":"J Kim","year":"2016","unstructured":"Kim, J. et al. Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors. Nat. Genet. 48, 600\u2013606 (2016).","journal-title":"Nat. Genet."},{"key":"958_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19633-9","volume":"11","author":"AA Yurchenko","year":"2020","unstructured":"Yurchenko, A. A. et al. XPC deficiency increases risk of hematologic malignancies through mutator phenotype and characteristic mutational signature. Nat. Commun. 11, 5834 (2020).","journal-title":"Nat. Commun."},{"key":"958_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-54223-z","volume":"15","author":"AB Silveira","year":"2024","unstructured":"Silveira, A. B. et al. Base-excision repair pathway shapes 5-methylcytosine deamination signatures in pan-cancer genomes. Nat. Commun. 15, 9864 (2024).","journal-title":"Nat. Commun."},{"key":"958_CR30","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.3390\/genes14112055","volume":"14","author":"E Sangiorgi","year":"2023","unstructured":"Sangiorgi, E. et al. Base-excision repair mutational signature in two sebaceous carcinomas of the eyelid. Genes 14, 2055 (2023).","journal-title":"Genes"},{"key":"958_CR31","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nm.4292","volume":"23","author":"H Davies","year":"2017","unstructured":"Davies, H. et al. HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. Nat. Med. 23, 517\u2013525 (2017).","journal-title":"Nat. Med."},{"key":"958_CR32","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature17676","volume":"534","author":"S Nik-Zainal","year":"2016","unstructured":"Nik-Zainal, S. et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature 534, 47\u201354 (2016).","journal-title":"Nature"},{"key":"958_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-019-0654-6","volume":"11","author":"G Rospo","year":"2019","unstructured":"Rospo, G. et al. Evolving neoantigen profiles in colorectal cancers with DNA repair defects. Genome Med. 11, 42 (2019).","journal-title":"Genome Med."},{"key":"958_CR34","doi-asserted-by":"publisher","first-page":"xii11","DOI":"10.1093\/annonc\/mdx681","volume":"28","author":"L Li","year":"2017","unstructured":"Li, L., Goedegebuure, S. P. & Gillanders, W. E. Preclinical and clinical development of neoantigen vaccines. Ann. Oncol. 28, xii11\u2013xii17 (2017).","journal-title":"Ann. Oncol."},{"key":"958_CR35","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.cell.2005.06.027","volume":"122","author":"Y Zhang","year":"2005","unstructured":"Zhang, Y. et al. Reconstitution of 5\u2032-directed human mismatch repair in a purified system. Cell 122, 693\u2013705 (2005).","journal-title":"Cell"},{"key":"958_CR36","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1146\/annurev.biochem.74.082803.133243","volume":"74","author":"TA Kunkel","year":"2005","unstructured":"Kunkel, T. A. & Erie, D. A. DNA mismatch repair. Annu. Rev. Biochem. 74, 681\u2013710 (2005).","journal-title":"Annu. Rev. Biochem."},{"key":"958_CR37","doi-asserted-by":"publisher","DOI":"10.1093\/narcan\/zcad031","volume":"5","author":"J Guan","year":"2023","unstructured":"Guan, J. & Li, G. M. DNA mismatch repair in cancer immunotherapy. NAR. Cancer 5, zcad031 (2023).","journal-title":"NAR. Cancer"},{"key":"958_CR38","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.138829","volume":"5","author":"HD Li","year":"2020","unstructured":"Li, H. D. et al. A PoleP286R mouse model of endometrial cancer recapitulates high mutational burden and immunotherapy response. JCI Insight 5, e138829 (2020).","journal-title":"JCI Insight"},{"key":"958_CR39","doi-asserted-by":"publisher","first-page":"3347","DOI":"10.1158\/1078-0432.CCR-15-0057","volume":"21","author":"IC van Gool","year":"2015","unstructured":"van Gool, I. C. et al. POLE proofreading mutations elicit an antitumor immune response in endometrial cancer. Clin. Cancer Res. 21, 3347\u20133355 (2015).","journal-title":"Clin. Cancer Res."},{"key":"958_CR40","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/ng.2503","volume":"45","author":"C Palles","year":"2013","unstructured":"Palles, C. et al. Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat. Genet. 45, 136\u2013144 (2013).","journal-title":"Nat. Genet."},{"key":"958_CR41","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/35015598","volume":"405","author":"RW Sobol","year":"2000","unstructured":"Sobol, R. W. et al. The lyase activity of the DNA repair protein \u03b2-polymerase protects from DNA-damage-induced cytotoxicity. Nature 405, 807\u2013810 (2000).","journal-title":"Nature"},{"key":"958_CR42","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1086\/431213","volume":"77","author":"SM Farrington","year":"2005","unstructured":"Farrington, S. M. et al. Germline susceptibility to colorectal cancer due to base-excision repair gene defects. Am. J. Hum. Genet. 77, 112\u2013119 (2005).","journal-title":"Am. J. Hum. Genet."},{"key":"958_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31341-0","volume":"13","author":"PS Robinson","year":"2022","unstructured":"Robinson, P. S. et al. Inherited MUTYH mutations cause elevated somatic mutation rates and distinctive mutational signatures in normal human cells. Nat. Commun. 13, 3949 (2022).","journal-title":"Nat. Commun."},{"key":"958_CR44","doi-asserted-by":"publisher","first-page":"23830","DOI":"10.1074\/jbc.M111.324947","volume":"287","author":"KA Donigan","year":"2012","unstructured":"Donigan, K. A. et al. Human POLB gene is mutated in high percentage of colorectal tumors. J. Biol. Chem. 287, 23830\u201323839 (2012).","journal-title":"J. Biol. Chem."},{"key":"958_CR45","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.3390\/cancers17132170","volume":"17","author":"M Szatkowska","year":"2025","unstructured":"Szatkowska, M. & Zdrada-Nowak, J. Genetic polymorphisms in base excision repair (BER) and nucleotide excision repair (NER) pathways as potential biomarkers for gynecological cancers: a comprehensive literature review. Cancers 17, 2170 (2025).","journal-title":"Cancers"},{"key":"958_CR46","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/bs.mie.2017.03.003","volume":"591","author":"CG Marsden","year":"2017","unstructured":"Marsden, C. G., Dragon, J. A., Wallace, S. S. & Sweasy, J. B. Base excision repair variants in cancer. Methods Enzymol. 591, 119\u2013157 (2017).","journal-title":"Methods Enzymol."},{"key":"958_CR47","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/carcin\/bgn250","volume":"30","author":"S Maynard","year":"2009","unstructured":"Maynard, S., Schurman, S. H., Harboe, C., de Souza-Pinto, N. C. & Bohr, V. A. Base excision repair of oxidative DNA damage and association with cancer and aging. Carcinogenesis 30, 2\u201310 (2009).","journal-title":"Carcinogenesis"},{"key":"958_CR48","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.canlet.2011.12.038","volume":"327","author":"SS Wallace","year":"2012","unstructured":"Wallace, S. S., Murphy, D. L. & Sweasy, J. B. Base excision repair and cancer. Cancer Lett. 327, 73\u201389 (2012).","journal-title":"Cancer Lett."},{"key":"958_CR49","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1038\/nrm2549","volume":"9","author":"PC Hanawalt","year":"2008","unstructured":"Hanawalt, P. C. & Spivak, G. Transcription-coupled DNA repair: two decades of progress and surprises. Nat. Rev. Mol. Cell Biol. 9, 958\u2013970 (2008).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"958_CR50","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.molcel.2010.02.009","volume":"37","author":"T Ogi","year":"2010","unstructured":"Ogi, T. et al. Three DNA polymerases, recruited by different mechanisms, carry out NER repair synthesis in human cells. Mol. Cell 37, 714\u2013727 (2010).","journal-title":"Mol. Cell"},{"key":"958_CR51","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/nrg2663","volume":"10","author":"JE Cleaver","year":"2009","unstructured":"Cleaver, J. E., Lam, E. T. & Revet, I. Disorders of nucleotide excision repair: the genetic and molecular basis of heterogeneity. Nat. Rev. Genet. 10, 756\u2013768 (2009).","journal-title":"Nat. Rev. Genet."},{"key":"958_CR52","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1038\/s41586-026-10122-5","volume":"652","author":"ECL Li","year":"2026","unstructured":"Li, E. C. L. et al. Pre-incision structures reveal principles of DNA nucleotide excision repair. Nature 652, 1060\u20131067 (2026).","journal-title":"Nature"},{"key":"958_CR53","doi-asserted-by":"publisher","unstructured":"Chambon, F. et al. Dramatic response to nivolumab in xeroderma pigmentosum skin tumor. Pediatr. Blood Cancer https:\/\/doi.org\/10.1002\/pbc.26837 (2018).","DOI":"10.1002\/pbc.26837"},{"key":"958_CR54","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.ejca.2017.02.026","volume":"77","author":"A Hauschild","year":"2017","unstructured":"Hauschild, A. et al. Regression of melanoma metastases and multiple non-melanoma skin cancers in xeroderma pigmentosum by the PD1-antibody pembrolizumab. Eur. J. Cancer 77, 84\u201387 (2017).","journal-title":"Eur. J. Cancer"},{"key":"958_CR55","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1111\/bjd.16270","volume":"178","author":"G Salomon","year":"2018","unstructured":"Salomon, G. et al. Efficacy of anti-programmed cell death-1 immunotherapy for skin carcinomas and melanoma metastases in a patient with xeroderma pigmentosum. Br. J. Dermatol. 178, 1199\u20131203 (2018).","journal-title":"Br. J. Dermatol."},{"key":"958_CR56","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/nrm2851","volume":"11","author":"ME Moynahan","year":"2010","unstructured":"Moynahan, M. E. & Jasin, M. Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis. Nat. Rev. Mol. Cell Biol. 11, 196\u2013207 (2010).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"958_CR57","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/cr.2008.3","volume":"18","author":"E Weterings","year":"2008","unstructured":"Weterings, E. & Chen, D. J. The endless tale of non-homologous end-joining. Cell Res. 18, 114\u2013124 (2008).","journal-title":"Cell Res."},{"key":"958_CR58","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.tcb.2015.07.009","volume":"26","author":"R Ceccaldi","year":"2016","unstructured":"Ceccaldi, R., Rondinelli, B. & D\u2019Andrea, A. D. Repair pathway choices and consequences at the double-strand break. Trends Cell Biol. 26, 52\u201364 (2016).","journal-title":"Trends Cell Biol."},{"key":"958_CR59","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1146\/annurev-cellbio-111822-014426","volume":"40","author":"A Sfeir","year":"2024","unstructured":"Sfeir, A., Tijsterman, M. & McVey, M. Microhomology-mediated end-joining chronicles: tracing the evolutionary footprints of genome protection. Annu. Rev. Cell Dev. Biol. 40, 195\u2013218 (2024).","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"958_CR60","doi-asserted-by":"publisher","first-page":"13587","DOI":"10.18632\/oncotarget.7277","volume":"7","author":"KC Strickland","year":"2016","unstructured":"Strickland, K. C. et al. Association and prognostic significance of BRCA1\/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1\/PD-L1 in high grade serous ovarian cancer. Oncotarget 7, 13587\u201313598 (2016).","journal-title":"Oncotarget"},{"key":"958_CR61","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0215381","volume":"14","author":"WX Wen","year":"2019","unstructured":"Wen, W. X. & Leong, C. O. Association of BRCA1- and BRCA2-deficiency with mutation burden, expression of PD-L1\/PD-1, immune infiltrates, and T cell-inflamed signature in breast cancer. PLoS ONE 14, e0215381 (2019).","journal-title":"PLoS ONE"},{"key":"958_CR62","doi-asserted-by":"publisher","first-page":"e1224","DOI":"10.1093\/oncolo\/oyae098","volume":"29","author":"O Mosalem","year":"2024","unstructured":"Mosalem, O. et al. A comprehensive analysis of POLE\/POLD1 genomic alterations in colorectal cancer. Oncologist 29, e1224\u2013e1227 (2024).","journal-title":"Oncologist"},{"key":"958_CR63","doi-asserted-by":"publisher","unstructured":"Jingyuan, W. et al. Genomic landscapes to characterize mismatch-repair deficiency (dMMR)\/microsatellite instability-high (MSI-H) gastrointestinal (GI) cancers stratified by tumor mutation burden (TMB). J. Clin. Oncol. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.26 (2023).","DOI":"10.1200\/JCO.2023.41.16_suppl.26"},{"key":"958_CR64","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/j.ccell.2025.05.014","volume":"43","author":"PP Vitiello","year":"2025","unstructured":"Vitiello, P. P. et al. Cisplatin and temozolomide combinatorial treatment triggers hypermutability and immune surveillance in experimental cancer models. Cancer Cell 43, 1296\u20131312 e1297 (2025).","journal-title":"Cancer Cell"},{"key":"958_CR65","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/j.ccell.2025.05.010","volume":"43","author":"B Rousseau","year":"2025","unstructured":"Rousseau, B. et al. Induction of a mismatch repair deficient genotype by tailored chemical mutagenesis in experimental models of cancer. Cancer Cell 43, 1313\u20131327.e10 (2025).","journal-title":"Cancer Cell"},{"key":"958_CR66","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/nature12305","volume":"498","author":"F Civril","year":"2013","unstructured":"Civril, F. et al. Structural mechanism of cytosolic DNA sensing by cGAS. Nature 498, 332\u2013337 (2013).","journal-title":"Nature"},{"key":"958_CR67","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1126\/science.1232458","volume":"339","author":"L Sun","year":"2013","unstructured":"Sun, L., Wu, J., Du, F., Chen, X. & Chen, Z. J. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 339, 786\u2013791 (2013). This seminal discovery identifies cGAS as the long-sought cytosolic DNA sensor that produces cGAMP and triggers STING-dependent innate immunity.","journal-title":"Science"},{"key":"958_CR68","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/s41586-022-05545-9","volume":"613","author":"MP Crossley","year":"2023","unstructured":"Crossley, M. P. et al. R-loop-derived cytoplasmic RNA\u2013DNA hybrids activate an immune response. Nature 613, 187\u2013194 (2023).","journal-title":"Nature"},{"key":"958_CR69","doi-asserted-by":"publisher","first-page":"eaat8657","DOI":"10.1126\/science.aat8657","volume":"363","author":"A Ablasser","year":"2019","unstructured":"Ablasser, A. & Chen, Z. J. cGAS in action: expanding roles in immunity and inflammation. Science 363, eaat8657 (2019).","journal-title":"Science"},{"key":"958_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07927-y","volume":"10","author":"AM Heijink","year":"2019","unstructured":"Heijink, A. M. et al. BRCA2 deficiency instigates cGAS-mediated inflammatory signaling and confers sensitivity to tumor necrosis factor-\u03b1-mediated cytotoxicity. Nat. Commun. 10, 100 (2019).","journal-title":"Nat. Commun."},{"key":"958_CR71","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41421-023-00601-8","volume":"9","author":"Y Huang","year":"2023","unstructured":"Huang, Y., Gu, L. & Li, G.-M. Heat shock protein DNAJA2 regulates transcription-coupled repair by triggering CSB degradation via chaperone-mediated autophagy. Cell Discov. 9, 107 (2023).","journal-title":"Cell Discov."},{"key":"958_CR72","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40952-0","volume":"14","author":"Y Huang","year":"2023","unstructured":"Huang, Y. et al. DNAJA2 deficiency activates cGAS\u2013STING pathway via the induction of aberrant mitosis and chromosome instability. Nat. Commun. 14, 5246 (2023).","journal-title":"Nat. Commun."},{"key":"958_CR73","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1126\/science.aad0095","volume":"350","author":"EM Van Allen","year":"2015","unstructured":"Van Allen, E. M. et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350, 207\u2013211 (2015).","journal-title":"Science"},{"key":"958_CR74","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1126\/science.aam7344","volume":"355","author":"CJ Lord","year":"2017","unstructured":"Lord, C. J. & Ashworth, A. PARP inhibitors: synthetic lethality in the clinic. Science 355, 1152\u20131158 (2017). This authoritative review chronicles the concept and clinical success of synthetic lethality between PARP inhibition and BRCA1\/2 deficiency, a paradigm for DDR-targeted therapy.","journal-title":"Science"},{"key":"958_CR75","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1158\/2159-8290.CD-15-0714","volume":"5","author":"PA Konstantinopoulos","year":"2015","unstructured":"Konstantinopoulos, P. A., Ceccaldi, R., Shapiro, G. I. & D\u2019Andrea, A. D. Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer. Cancer Discov. 5, 1137\u20131154 (2015).","journal-title":"Cancer Discov."},{"key":"958_CR76","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/S0960-9822(99)80479-5","volume":"9","author":"A Tutt","year":"1999","unstructured":"Tutt, A. et al. Absence of Brca2 causes genome instability by chromosome breakage and loss associated with centrosome amplification. Curr. Biol. 9, 1107\u20131110 (1999).","journal-title":"Curr. Biol."},{"key":"958_CR77","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-64578-6","volume":"16","author":"K Situ","year":"2025","unstructured":"Situ, K. et al. BRCA2 deficiency and replication stress drive APOBEC3-mediated genomic instability. Nat. Commun. 16, 9544 (2025).","journal-title":"Nat. Commun."},{"key":"958_CR78","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1126\/science.1257216","volume":"347","author":"RL Flynn","year":"2015","unstructured":"Flynn, R. L. et al. Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors. Science 347, 273\u2013277 (2015).","journal-title":"Science"},{"key":"958_CR79","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/nature23470","volume":"548","author":"SM Harding","year":"2017","unstructured":"Harding, S. M. et al. Mitotic progression following DNA damage enables pattern recognition within micronuclei. Nature 548, 466\u2013470 (2017).","journal-title":"Nature"},{"key":"958_CR80","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50999-2","volume":"15","author":"Y Sun","year":"2024","unstructured":"Sun, Y. et al. 53BP1 loss elicits cGAS\u2013STING-dependent antitumor immunity in ovarian and pancreatic cancer. Nat. Commun. 15, 6676 (2024).","journal-title":"Nat. Commun."},{"key":"958_CR81","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.pbiomolbio.2020.11.005","volume":"161","author":"RM Williams","year":"2021","unstructured":"Williams, R. M. & Zhang, X. Roles of ATM and ATR in DNA double strand breaks and replication stress. Prog. Biophys. Mol. Biol. 161, 27\u201338 (2021).","journal-title":"Prog. Biophys. Mol. Biol."},{"key":"958_CR82","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.ado4618","volume":"10","author":"H Taniguchi","year":"2024","unstructured":"Taniguchi, H. et al. ATR inhibition activates cancer cell cGAS\/STING\u2013interferon signaling and promotes antitumor immunity in small-cell lung cancer. Sci. Adv. 10, eado4618 (2024).","journal-title":"Sci. Adv."},{"key":"958_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2025.156980","volume":"193","author":"N van Campen","year":"2025","unstructured":"van Campen, N. et al. ATM and ATR inhibition increases radiosensitivity and cGAS\u2013STING activation in prostate cancer. Cytokine 193, 156980 (2025).","journal-title":"Cytokine"},{"key":"958_CR84","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.3390\/cancers13153733","volume":"13","author":"M Proctor","year":"2021","unstructured":"Proctor, M. et al. Targeting replication stress using CHK1 inhibitor promotes innate and NKT cell immune responses and tumour regression. Cancers 13, 3733 (2021).","journal-title":"Cancers"},{"key":"958_CR85","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1158\/2159-8290.CD-18-1020","volume":"9","author":"T Sen","year":"2019","unstructured":"Sen, T. et al. Targeting DNA damage response promotes antitumor immunity through STING-mediated T-cell activation in small cell lung cancer. Cancer Discov. 9, 646\u2013661 (2019).","journal-title":"Cancer Discov."},{"key":"958_CR86","doi-asserted-by":"publisher","first-page":"4898","DOI":"10.1158\/1078-0432.CCR-21-1010","volume":"27","author":"Z Tang","year":"2021","unstructured":"Tang, Z. et al. ATR inhibition induces CDK1\u2013SPOP signaling and enhances anti-PD-L1 cytotoxicity in prostate cancer. Clin. Cancer Res. 27, 4898\u20134909 (2021).","journal-title":"Clin. Cancer Res."},{"key":"958_CR87","doi-asserted-by":"publisher","first-page":"5951","DOI":"10.1172\/JCI130445","volume":"130","author":"L Wang","year":"2020","unstructured":"Wang, L. et al. Inhibition of the ATM\/Chk2 axis promotes cGAS\/STING signaling in ARID1A-deficient tumors. J. Clin. Invest. 130, 5951\u20135966 (2020).","journal-title":"J. Clin. Invest."},{"key":"958_CR88","doi-asserted-by":"publisher","first-page":"14900","DOI":"10.3390\/ijms241914900","volume":"24","author":"S Zahnreich","year":"2023","unstructured":"Zahnreich, S., El Guerzyfy, S., Kaufmann, J. & Schmidberger, H. The cGAS\/STING\/IFN-1 response in squamous head and neck cancer cells after genotoxic challenges and abrogation of the ATR-Chk1 and Fanconi anemia axis. Int. J. Mol. Sci. 24, 14900 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"958_CR89","doi-asserted-by":"publisher","DOI":"10.1172\/JCI139333","volume":"131","author":"M Hu","year":"2021","unstructured":"Hu, M. et al. ATM inhibition enhances cancer immunotherapy by promoting mtDNA leakage and cGAS\/STING activation. J. Clin. Invest. 131, e139333 (2021).","journal-title":"J. Clin. Invest."},{"key":"958_CR90","doi-asserted-by":"publisher","first-page":"933","DOI":"10.3389\/fgene.2020.00933","volume":"11","author":"R Yi","year":"2020","unstructured":"Yi, R. et al. ATM mutations benefit bladder cancer patients treated with immune checkpoint inhibitors by acting on the tumor immune microenvironment. Front. Genet. 11, 933 (2020).","journal-title":"Front. Genet."},{"key":"958_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2020.153032","volume":"216","author":"L Sun","year":"2020","unstructured":"Sun, L., Wang, R. C., Zhang, Q. & Guo, L. L. ATM mutations as an independent prognostic factor and potential biomarker for immune checkpoint therapy in endometrial cancer. Pathol. Res. Pract. 216, 153032 (2020).","journal-title":"Pathol. Res. Pract."},{"key":"958_CR92","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010548","volume":"13","author":"S Sinha","year":"2025","unstructured":"Sinha, S. et al. The cold immunological landscape of ATM-deficient cancers. J. Immunother. Cancer 13, e010548 (2025).","journal-title":"J. Immunother. Cancer"},{"key":"958_CR93","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1159\/000540573","volume":"17","author":"H Ferreira Bruzzi Porto","year":"2024","unstructured":"Ferreira Bruzzi Porto, H. et al. A complete response to combined immunotherapy in a patient with an ATM plus SF3B1 mutation and a moderate tumor mutational burden with a high-grade treatment-emergent neuroendocrine prostate cancer: case report and review of the literature. Case Rep. Oncol. 17, 950\u2013959 (2024).","journal-title":"Case Rep. Oncol."},{"key":"958_CR94","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.21873\/anticanres.17015","volume":"44","author":"JE Shin","year":"2024","unstructured":"Shin, J. E. & Kim, S. T. DNA checkpoint gene mutation as a biomarker for immune checkpoint inhibitor therapy in advanced biliary tract cancer. Anticancer. Res. 44, 2103\u20132108 (2024).","journal-title":"Anticancer. Res."},{"key":"958_CR95","doi-asserted-by":"publisher","first-page":"501","DOI":"10.2174\/0115680096250376231025062652","volume":"24","author":"S Cui","year":"2024","unstructured":"Cui, S. et al. Identification of ATM mutation as a potential prognostic biomarker for immune checkpoint inhibitors therapy. Curr. Cancer Drug Targets 24, 501\u2013509 (2024).","journal-title":"Curr. Cancer Drug Targets"},{"key":"958_CR96","doi-asserted-by":"publisher","DOI":"10.1172\/JCI187371","volume":"135","author":"V Cancila","year":"2025","unstructured":"Cancila, V. et al. Aggressive B cell lymphomas retain ATR-dependent determinants of T cell exclusion from the germinal center dark zone. J. Clin. Invest. 135, e187371 (2025).","journal-title":"J. Clin. Invest."},{"key":"958_CR97","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1158\/2326-6066.CIR-25-0743","volume":"14","author":"A Sakrepatna Nagaraj","year":"2026","unstructured":"Sakrepatna Nagaraj, A. et al. Ex vivo immuno-oncology platform reveals spatial T-cell infiltration patterns linked to ATR inhibition responses in high-grade serous ovarian cancer. Cancer Immunol. Res. 14, 625\u2013639 (2026).","journal-title":"Cancer Immunol. Res."},{"key":"958_CR98","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115320","volume":"219","author":"K Steger","year":"2025","unstructured":"Steger, K. et al. Differences in immunogenicity of TP53-mutated cancers with low tumor mutational burden (TMB). A study on TP53mut endometrial-, ovarian- and triple-negative breast cancer. Eur. J. Cancer 219, 115320 (2025).","journal-title":"Eur. J. Cancer"},{"key":"958_CR99","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1053\/j.gastro.2008.04.040","volume":"135","author":"FM Speetjens","year":"2008","unstructured":"Speetjens, F. M., Kuppen, P. J., Morreau, H. & van der Burg, S. H. Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers. Gastroenterology 135, 711\u2013712 (2008).","journal-title":"Gastroenterology"},{"key":"958_CR100","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1053\/j.gastro.2008.01.015","volume":"134","author":"Y Schwitalle","year":"2008","unstructured":"Schwitalle, Y. et al. Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers. Gastroenterology 134, 988\u2013997 (2008).","journal-title":"Gastroenterology"},{"key":"958_CR101","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1158\/1078-0432.CCR-18-1984","volume":"25","author":"HH Yoon","year":"2019","unstructured":"Yoon, H. H. et al. Intertumoral heterogeneity of CD3+ and CD8+ T-cell densities in the microenvironment of DNA mismatch-repair-deficient colon cancers: implications for prognosis. Clin. Cancer Res. 25, 125\u2013133 (2019).","journal-title":"Clin. Cancer Res."},{"key":"958_CR102","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1158\/2159-8290.CD-17-0226","volume":"7","author":"KW Mouw","year":"2017","unstructured":"Mouw, K. W., Goldberg, M. S., Konstantinopoulos, P. A. & D\u2019Andrea, A. D. DNA damage and repair biomarkers of immunotherapy response. Cancer Discov. 7, 675\u2013693 (2017). This influential review integrates the emerging field of DDR defects as predictive biomarkers for immune checkpoint blockade, bridging DNA repair and tumour immunology.","journal-title":"Cancer Discov."},{"key":"958_CR103","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1158\/2326-6066.CIR-15-0044","volume":"3","author":"T Higuchi","year":"2015","unstructured":"Higuchi, T. et al. CTLA-4 blockade synergizes therapeutically with PARP inhibition in BRCA1-deficient ovarian cancer. Cancer Immunol. Res. 3, 1257\u20131268 (2015).","journal-title":"Cancer Immunol. Res."},{"key":"958_CR104","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.21037\/atm-21-5449","volume":"9","author":"Y Xiao","year":"2021","unstructured":"Xiao, Y. et al. Comprehensive analysis of DNA damage repair deficiency in 10,284 pan-cancer study. Ann. Transl. Med. 9, 1661 (2021).","journal-title":"Ann. Transl. Med."},{"key":"958_CR105","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1158\/2159-8290.CD-14-0863","volume":"5","author":"NJ Llosa","year":"2015","unstructured":"Llosa, N. J. et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 5, 43\u201351 (2015). This paper characterizes the immune landscape of MMR-deficient tumours, revealing high T cell infiltration and expression of multiple immune checkpoints that explain sensitivity to PD1 blockade.","journal-title":"Cancer Discov."},{"key":"958_CR106","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01883-9","volume":"8","author":"H Sato","year":"2017","unstructured":"Sato, H. et al. DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells. Nat. Commun. 8, 1751 (2017).","journal-title":"Nat. Commun."},{"key":"958_CR107","doi-asserted-by":"publisher","DOI":"10.1016\/j.dnarep.2023.103594","volume":"133","author":"Y Zhou","year":"2024","unstructured":"Zhou, Y. & Mouw, K. W. DNA repair deficiency and the immune microenvironment: a pathways perspective. DNA Repair\u00a0133, 103594 (2024).","journal-title":"DNA Repair"},{"key":"958_CR108","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.semcdb.2016.09.011","volume":"63","author":"H Schuhwerk","year":"2017","unstructured":"Schuhwerk, H., Atteya, R., Siniuk, K. & Wang, Z. Q. PARPing for balance in the homeostasis of poly(ADP-ribosyl)ation. Semin. Cell Dev. Biol. 63, 81\u201391 (2017).","journal-title":"Semin. Cell Dev. Biol."},{"key":"958_CR109","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nrm3376","volume":"13","author":"BA Gibson","year":"2012","unstructured":"Gibson, B. A. & Kraus, W. L. New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs. Nat. Rev. Mol. Cell Biol. 13, 411\u2013424 (2012).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"958_CR110","doi-asserted-by":"publisher","first-page":"4257","DOI":"10.1158\/1078-0432.CCR-15-0887","volume":"21","author":"G Kim","year":"2015","unstructured":"Kim, G. et al. FDA approval summary: olaparib monotherapy in patients with deleterious germline BRCA-mutated advanced ovarian cancer treated with three or more lines of chemotherapy. Clin. Cancer Res. 21, 4257\u20134261 (2015). This approval summary marks the first FDA authorization of a DDR-targeted agent (olaparib) for BRCA-mutated cancer, a milestone in precision oncology.","journal-title":"Clin. Cancer Res."},{"key":"958_CR111","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1146\/annurev-cancerbio-030518-055914","volume":"3","author":"J Murai","year":"2019","unstructured":"Murai, J. & Pommier, Y. PARP trapping beyond homologous recombination and platinum sensitivity in cancers. Annu. Rev. Cancer Biol. 3, 131\u2013150 (2019).","journal-title":"Annu. Rev. Cancer Biol."},{"key":"958_CR112","doi-asserted-by":"publisher","first-page":"7158","DOI":"10.1128\/MCB.25.16.7158-7169.2005","volume":"25","author":"N Saleh-Gohari","year":"2005","unstructured":"Saleh-Gohari, N. et al. Spontaneous homologous recombination is induced by collapsed replication forks that are caused by endogenous DNA single-strand breaks. Mol. Cell Biol. 25, 7158\u20137169 (2005).","journal-title":"Mol. Cell Biol."},{"key":"958_CR113","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1016\/S1470-2045(21)00531-3","volume":"22","author":"S Banerjee","year":"2021","unstructured":"Banerjee, S. et al. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1\/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 22, 1721\u20131731 (2021).","journal-title":"Lancet Oncol."},{"key":"958_CR114","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1200\/JCO.22.01549","volume":"41","author":"P DiSilvestro","year":"2023","unstructured":"DiSilvestro, P. et al. Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1\/GOG 3004 trial. J. Clin. Oncol. 41, 609\u2013617 (2023).","journal-title":"J. Clin. Oncol."},{"key":"958_CR115","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1056\/NEJMoa1802905","volume":"379","author":"JK Litton","year":"2018","unstructured":"Litton, J. K. et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N. Engl. J. Med. 379, 753\u2013763 (2018).","journal-title":"N. Engl. J. Med."},{"key":"958_CR116","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","volume":"377","author":"M Robson","year":"2017","unstructured":"Robson, M. et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N. Engl. J. Med. 377, 523\u2013533 (2017).","journal-title":"N. Engl. J. Med."},{"key":"958_CR117","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","volume":"382","author":"J de Bono","year":"2020","unstructured":"de Bono, J. et al. Olaparib for metastatic castration-resistant prostate cancer. N. Engl. J. Med. 382, 2091\u20132102 (2020).","journal-title":"N. Engl. J. Med."},{"key":"958_CR118","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1056\/NEJMoa2214676","volume":"388","author":"K Fizazi","year":"2023","unstructured":"Fizazi, K. et al. Rucaparib or physician\u2019s choice in metastatic prostate cancer. N. Engl. J. Med. 388, 719\u2013732 (2023).","journal-title":"N. Engl. J. Med."},{"key":"958_CR119","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","volume":"373","author":"J Mateo","year":"2015","unstructured":"Mateo, J. et al. DNA-repair defects and olaparib in metastatic prostate cancer. N. Engl. J. Med. 373, 1697\u20131708 (2015).","journal-title":"N. Engl. J. Med."},{"key":"958_CR120","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-35880-y","volume":"14","author":"T Tsujino","year":"2023","unstructured":"Tsujino, T. et al. CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer. Nat. Commun. 14, 252 (2023).","journal-title":"Nat. Commun."},{"key":"958_CR121","doi-asserted-by":"publisher","first-page":"4274","DOI":"10.1200\/JCO.20.02151","volume":"38","author":"NM Tung","year":"2020","unstructured":"Tung, N. M. et al. TBCRC 048: phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes. J. Clin. Oncol. 38, 4274\u20134282 (2020).","journal-title":"J. Clin. Oncol."},{"key":"958_CR122","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.ccell.2020.03.007","volume":"37","author":"A Marusyk","year":"2020","unstructured":"Marusyk, A., Janiszewska, M. & Polyak, K. Intratumor heterogeneity: the Rosetta Stone of therapy resistance. Cancer Cell 37, 471\u2013484 (2020).","journal-title":"Cancer Cell"},{"key":"958_CR123","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1158\/2159-8290.CD-19-1485","volume":"10","author":"SJ Pettitt","year":"2020","unstructured":"Pettitt, S. J. et al. Clinical BRCA1\/2 reversion analysis identifies hotspot mutations and predicted neoantigens associated with therapy resistance. Cancer Discov. 10, 1475\u20131488 (2020).","journal-title":"Cancer Discov."},{"key":"958_CR124","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/s41556-018-0140-1","volume":"20","author":"H Dev","year":"2018","unstructured":"Dev, H. et al. Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells. Nat. Cell Biol. 20, 954\u2013965 (2018).","journal-title":"Nat. Cell Biol."},{"key":"958_CR125","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nrm3546","volume":"14","author":"Y Shiloh","year":"2013","unstructured":"Shiloh, Y. & Ziv, Y. The ATM protein kinase: regulating the cellular response to genotoxic stress, and more.\u00a0Nat. Rev. Mol. Cell Biol. 14, 197\u2013210 (2013).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"958_CR126","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/nrm.2017.67","volume":"18","author":"JC Saldivar","year":"2017","unstructured":"Saldivar, J. C., Cortez, D. & Cimprich, K. A. The essential kinase ATR: ensuring faithful duplication of a challenging genome. Nat. Rev. Mol. Cell Biol. 18, 622\u2013636 (2017).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"958_CR127","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s11523-025-01136-6","volume":"20","author":"EA Ampolini","year":"2025","unstructured":"Ampolini, E. A., Jimenez-Sainz, J. & Long, D. T. The development of ATM inhibitors in cancer therapy. Target. Oncol. 20, 281\u2013297 (2025).","journal-title":"Target. Oncol."},{"key":"958_CR128","doi-asserted-by":"publisher","first-page":"2800","DOI":"10.1158\/1078-0432.CCR-22-2444","volume":"29","author":"SL Wethington","year":"2023","unstructured":"Wethington, S. L. et al. Combination ATR (ceralasertib) and PARP (olaparib) inhibitor (CAPRI) trial in acquired PARP inhibitor-resistant homologous recombination-deficient ovarian cancer. Clin. Cancer Res. 29, 2800\u20132807 (2023).","journal-title":"Clin. Cancer Res."},{"key":"958_CR129","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S1470-2045(20)30180-7","volume":"21","author":"PA Konstantinopoulos","year":"2020","unstructured":"Konstantinopoulos, P. A. et al. Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 21, 957\u2013968 (2020).","journal-title":"Lancet Oncol."},{"key":"958_CR130","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06911-3","volume":"15","author":"C Li","year":"2024","unstructured":"Li, C. et al. ATM inhibition enhance immunotherapy by activating STING signaling and augmenting MHC class I. Cell Death Dis. 15, 519 (2024).","journal-title":"Cell Death Dis."},{"key":"958_CR131","doi-asserted-by":"publisher","first-page":"3940","DOI":"10.1158\/0008-5472.CAN-19-0761","volume":"79","author":"Q Zhang","year":"2019","unstructured":"Zhang, Q. et al. Inhibition of ATM increases interferon signaling and sensitizes pancreatic cancer to immune checkpoint blockade therapy. Cancer Res. 79, 3940\u20133951 (2019).","journal-title":"Cancer Res."},{"key":"958_CR132","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.3390\/cells12091288","volume":"12","author":"C-H Huang","year":"2023","unstructured":"Huang, C.-H. et al. ATM inhibition-induced ISG15\/IFI27\/OASL is correlated with immunotherapy response and inflamed immunophenotype. Cells 12, 1288 (2023).","journal-title":"Cells"},{"key":"958_CR133","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1101\/gad.351084.123","volume":"37","author":"M Wang","year":"2023","unstructured":"Wang, M. et al. ATR inhibition induces synthetic lethality in mismatch repair-deficient cells and augments immunotherapy. Genes Dev. 37, 929\u2013943 (2023).","journal-title":"Genes Dev."},{"key":"958_CR134","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000340","volume":"8","author":"H Sheng","year":"2020","unstructured":"Sheng, H. et al. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma. J. Immunother. Cancer 8, e000340 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"958_CR135","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1182\/blood-2015-05-644872","volume":"127","author":"M Kwok","year":"2016","unstructured":"Kwok, M. et al. ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells. Blood 127, 582\u2013595 (2016).","journal-title":"Blood"},{"key":"958_CR136","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45996-4","volume":"15","author":"EL Hardaker","year":"2024","unstructured":"Hardaker, E. L. et al. The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment. Nat. Commun. 15, 1700 (2024).","journal-title":"Nat. Commun."},{"key":"958_CR137","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/s41591-024-02808-y","volume":"30","author":"B Besse","year":"2024","unstructured":"Besse, B. et al. Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial. Nat. Med. 30, 716\u2013729 (2024).","journal-title":"Nat. Med."},{"key":"958_CR138","unstructured":"AstraZeneca. Update on LATIFY phase III trial of ceralasertib plus Imfinzi in previously treated advanced non-small cell lung cancer [Press release]. AstraZeneca https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2025\/update-on-latify-phase-iii-trial.html (2025)."},{"key":"958_CR139","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00655-1","volume":"8","author":"S Camfield","year":"2024","unstructured":"Camfield, S. et al. Secrets of DNA-PKcs beyond DNA repair. npj Precis. Oncol. 8, 154 (2024).","journal-title":"npj Precis. Oncol."},{"key":"958_CR140","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT02516813 (2024)."},{"key":"958_CR141","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT01353625 (2021)."},{"key":"958_CR142","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT04533750 (2026)."},{"key":"958_CR143","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT02977780 (2025)."},{"key":"958_CR144","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT03907969 (2024)."},{"key":"958_CR145","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT03579628 (2022)."},{"key":"958_CR146","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2025.111943","volume":"28","author":"C De Rosa","year":"2025","unstructured":"De Rosa, C. et al. DNA-PK inhibition sustains the antitumor innate immune response in small cell lung cancer. iScience 28, 111943 (2025).","journal-title":"iScience"},{"key":"958_CR147","doi-asserted-by":"publisher","first-page":"4353","DOI":"10.1158\/1078-0432.CCR-20-3701","volume":"27","author":"K Nakamura","year":"2021","unstructured":"Nakamura, K. et al. Inhibition of DNA-PK with AZD7648 sensitizes tumor cells to radiotherapy and induces type I IFN-dependent durable tumor control. Clin. Cancer Res. 27, 4353\u20134366 (2021).","journal-title":"Clin. Cancer Res."},{"key":"958_CR148","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.ijrobp.2023.09.024","volume":"118","author":"M Samuels","year":"2024","unstructured":"Samuels, M. et al. A phase 1 study of the DNA-PK inhibitor peposertib in combination with radiation therapy with or without cisplatin in patients with advanced head and neck tumors. Int. J. Radiat. Oncol. Biol. Phys. 118, 743\u2013756 (2024).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"958_CR149","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1093\/nar\/gkac071","volume":"50","author":"D Niewolik","year":"2022","unstructured":"Niewolik, D. & Schwarz, K. Physical ARTEMIS:DNA-PKcs interaction is necessary for V(D)J recombination. Nucleic Acids Res. 50, 2096\u20132110 (2022).","journal-title":"Nucleic Acids Res."},{"key":"958_CR150","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2021.101209","volume":"297","author":"ZJ Waldrip","year":"2021","unstructured":"Waldrip, Z. J. et al. DNA-PKcs kinase activity stabilizes the transcription factor Egr1 in activated immune cells. J. Biol. Chem. 297, 101209 (2021).","journal-title":"J. Biol. Chem."},{"key":"958_CR151","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/0092-8674(95)90116-7","volume":"83","author":"JF McBlane","year":"1995","unstructured":"McBlane, J. F. et al. Cleavage at a V(D)J recombination signal requires only RAG1 and RAG2 proteins and occurs in two steps. Cell 83, 387\u2013395 (1995).","journal-title":"Cell"},{"key":"958_CR152","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S0092-8674(02)00671-2","volume":"108","author":"Y Ma","year":"2002","unstructured":"Ma, Y., Pannicke, U., Schwarz, K. & Lieber, M. R. Hairpin opening and overhang processing by an Artemis\/DNA-dependent protein kinase complex in nonhomologous end joining and V(D)J recombination. Cell 108, 781\u2013794 (2002).","journal-title":"Cell"},{"key":"958_CR153","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.molcel.2008.05.029","volume":"31","author":"H Lu","year":"2008","unstructured":"Lu, H. et al. A biochemically defined system for coding joint formation in V(D)J recombination. Mol. Cell 31, 485\u2013497 (2008).","journal-title":"Mol. Cell"},{"key":"958_CR154","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1111\/imcb.12651","volume":"101","author":"AC Azevedo-Pouly","year":"2023","unstructured":"Azevedo-Pouly, A. C. et al. Chemical inhibition of DNA-PKcs impairs the activation and cytotoxicity of CD4+ helper and CD8+ effector T cells. Immunol. Cell Biol. 101, 663\u2013671 (2023).","journal-title":"Immunol. Cell Biol."},{"key":"958_CR155","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.116796","volume":"45","author":"RR Rainwater","year":"2026","unstructured":"Rainwater, R. R. et al. DNA-PKcs controls the cytotoxic T cell response to cancer and transplant allograft through regulating LAT-dependent signaling. Cell Rep. 45, 116796 (2026).","journal-title":"Cell Rep."},{"key":"958_CR156","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1021\/jm501026z","volume":"58","author":"M Andrs","year":"2015","unstructured":"Andrs, M. et al. Phosphatidylinositol 3-kinase (PI3K) and phosphatidylinositol 3-kinase-related kinase (PIKK) inhibitors: importance of the morpholine ring. J. Med. Chem. 58, 41\u201371 (2015).","journal-title":"J. Med. Chem."},{"key":"958_CR157","doi-asserted-by":"publisher","first-page":"2574","DOI":"10.1158\/0008-5472.CAN-12-1702","volume":"73","author":"Q Liu","year":"2013","unstructured":"Liu, Q. et al. Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR. Cancer Res. 73, 2574\u20132586 (2013).","journal-title":"Cancer Res."},{"key":"958_CR158","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/s41591-020-0805-8","volume":"26","author":"M Chalabi","year":"2020","unstructured":"Chalabi, M. et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat. Med. 26, 566\u2013576 (2020).","journal-title":"Nat. Med."},{"key":"958_CR159","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1056\/NEJMoa2400634","volume":"390","author":"M Chalabi","year":"2024","unstructured":"Chalabi, M. et al. Neoadjuvant immunotherapy in locally advanced mismatch repair-deficient colon cancer. N. Engl. J. Med. 390, 1949\u20131958 (2024).","journal-title":"N. Engl. J. Med."},{"key":"958_CR160","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","volume":"383","author":"T Andr\u00e9","year":"2020","unstructured":"Andr\u00e9, T. et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N. Engl. J. Med. 383, 2207\u20132218 (2020).","journal-title":"N. Engl. J. Med."},{"key":"958_CR161","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1200\/JCO.2025.43.4_suppl.179","volume":"43","author":"M O\u2019Neill","year":"2025","unstructured":"O\u2019Neill, M. et al. Neoadjuvant immunotherapy for locally advanced\/metastatic mismatch repair deficient colorectal cancer: a two-year institutional experience. J. Clin. Oncol. 43, 179\u2013179 (2025).","journal-title":"J. Clin. Oncol."},{"key":"958_CR162","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1056\/NEJMoa2404512","volume":"392","author":"A Cercek","year":"2025","unstructured":"Cercek, A. et al. Nonoperative management of mismatch repair-deficient tumors. N. Engl. J. Med. 392, 2297\u20132308 (2025).","journal-title":"N. Engl. J. Med."},{"key":"958_CR163","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.molcel.2022.12.031","volume":"83","author":"K Concannon","year":"2023","unstructured":"Concannon, K., Morris, B. B., Gay, C. M. & Byers, L. A. Combining targeted DNA repair inhibition and immune-oncology approaches for enhanced tumor control. Mol. Cell 83, 660\u2013680 (2023).","journal-title":"Mol. Cell"},{"key":"958_CR164","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.cell.2015.03.030","volume":"161","author":"P Sharma","year":"2015","unstructured":"Sharma, P. & Allison, J. P. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161, 205\u2013214 (2015).","journal-title":"Cell"},{"key":"958_CR165","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi, N. A. et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124\u2013128 (2015). This pioneering study shows that higher non-synonymous mutation burden correlates with clinical benefit from pembrolizumab in lung cancer, extending the mutation\u2013immunogenicity link beyond MMR deficiency.","journal-title":"Science"},{"key":"958_CR166","doi-asserted-by":"publisher","DOI":"10.1016\/j.dnarep.2022.103409","volume":"120","author":"EM Barros","year":"2022","unstructured":"Barros, E. M., McIntosh, S. A. & Savage, K. I. The DNA damage induced immune response: implications for cancer therapy. DNA Repair. 120, 103409 (2022).","journal-title":"DNA Repair."},{"key":"958_CR167","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/nrd3626","volume":"11","author":"L Galluzzi","year":"2012","unstructured":"Galluzzi, L., Senovilla, L., Zitvogel, L. & Kroemer, G. The secret ally: immunostimulation by anticancer drugs. Nat. Rev. Drug Discov. 11, 215\u2013233 (2012).","journal-title":"Nat. Rev. Drug Discov."},{"key":"958_CR168","doi-asserted-by":"publisher","DOI":"10.4161\/onci.28518","volume":"3","author":"EB Golden","year":"2014","unstructured":"Golden, E. B. et al. Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death. Oncoimmunology 3, e28518 (2014).","journal-title":"Oncoimmunology"},{"key":"958_CR169","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/nature14292","volume":"520","author":"C Twyman-Saint Victor","year":"2015","unstructured":"Twyman-Saint Victor, C. et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520, 373\u2013377 (2015).","journal-title":"Nature"},{"key":"958_CR170","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(23)00540-5","volume":"25","author":"E Grande","year":"2024","unstructured":"Grande, E. et al. Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study. Lancet Oncol. 25, 29\u201345 (2024).","journal-title":"Lancet Oncol."},{"key":"958_CR171","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1346225","volume":"14","author":"H Gao","year":"2024","unstructured":"Gao, H. et al. Platinum-based neoadjuvant chemotherapy upregulates STING\/IFN pathway expression and promotes TILs infiltration in NSCLC. Front. Oncol. 14, 1346225 (2024).","journal-title":"Front. Oncol."},{"key":"958_CR172","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.ccell.2015.10.012","volume":"28","author":"L Galluzzi","year":"2015","unstructured":"Galluzzi, L., Buque, A., Kepp, O., Zitvogel, L. & Kroemer, G. Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell 28, 690\u2013714 (2015).","journal-title":"Cancer Cell"},{"key":"958_CR173","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2024.2447403","volume":"57","author":"G Li","year":"2025","unstructured":"Li, G. et al. The role of cisplatin in modulating the tumor immune microenvironment and its combination therapy strategies: a new approach to enhance anti-tumor efficacy. Ann. Med. 57, 2447403 (2025).","journal-title":"Ann. Med."},{"key":"958_CR174","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","volume":"391","author":"T Powles","year":"2024","unstructured":"Powles, T. et al. Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer. N. Engl. J. Med. 391, 1773\u20131786 (2024).","journal-title":"N. Engl. J. Med."},{"key":"958_CR175","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi, L. et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N. Engl. J. Med. 378, 2078\u20132092 (2018).","journal-title":"N. Engl. J. Med."},{"key":"958_CR176","doi-asserted-by":"publisher","first-page":"3610","DOI":"10.1200\/JCO-25-00036","volume":"43","author":"JD Bradley","year":"2025","unstructured":"Bradley, J. D. et al. Simultaneous durvalumab and platinum-based chemoradiotherapy in unresectable stage III non-small cell lung cancer: the phase III PACIFIC-2 study. J. Clin. Oncol. 43, 3610\u20133621 (2025).","journal-title":"J. Clin. Oncol."},{"key":"958_CR177","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S1470-2045(24)00100-1","volume":"25","author":"JP Machiels","year":"2024","unstructured":"Machiels, J. P. et al. Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial. Lancet Oncol. 25, 572\u2013587 (2024).","journal-title":"Lancet Oncol."},{"key":"958_CR178","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1001\/jamaoncol.2019.1478","volume":"5","author":"W Theelen","year":"2019","unstructured":"Theelen, W. et al. Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial. JAMA Oncol. 5, 1276\u20131282 (2019).","journal-title":"JAMA Oncol."},{"key":"958_CR179","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1158\/2159-8290.CD-18-1218","volume":"9","author":"C Pantelidou","year":"2019","unstructured":"Pantelidou, C. et al. PARP inhibitor efficacy depends on CD8+ T-cell recruitment via intratumoral STING pathway activation in BRCA-deficient models of triple-negative breast cancer. Cancer Discov. 9, 722\u2013737 (2019).","journal-title":"Cancer Discov."},{"key":"958_CR180","doi-asserted-by":"publisher","first-page":"118.08","DOI":"10.4049\/jimmunol.208.Supp.118.08","volume":"208","author":"DM Falcon","year":"2022","unstructured":"Falcon, D. M. & Adams, S. F. The PARP inhibitor ABT-888 impairs the suppressive capacity of regulatory T cells through modulation of FoxP3 and CTLA-4. J. Immunol. 208, 118.08 (2022).","journal-title":"J. Immunol."},{"key":"958_CR181","doi-asserted-by":"publisher","first-page":"4905","DOI":"10.1016\/j.cell.2024.06.013","volume":"187","author":"Y Luo","year":"2024","unstructured":"Luo, Y. et al. Neoadjuvant PARPi or chemotherapy in ovarian cancer informs targeting effector Treg cells for homologous-recombination-deficient tumors. Cell 187, 4905\u20134925 e4924 (2024). This study reveals that PARPis selectively deplete effector Treg cells in HR-deficient tumours, uncovering a novel immunomodulatory mechanism beyond STING.","journal-title":"Cell"},{"key":"958_CR182","doi-asserted-by":"publisher","first-page":"2972","DOI":"10.1016\/j.celrep.2018.11.054","volume":"25","author":"L Ding","year":"2018","unstructured":"Ding, L. et al. PARP inhibition elicits STING-dependent antitumor immunity in Brca1-deficient ovarian cancer. Cell Rep. 25, 2972\u20132980.e2975 (2018). This mechanistic study demonstrates that PARPis activate the cGAS\u2013STING pathway and enhance antitumour immunity, providing a rationale for combining PARPis with immunotherapy.","journal-title":"Cell Rep."},{"key":"958_CR183","doi-asserted-by":"publisher","first-page":"3711","DOI":"10.1158\/1078-0432.CCR-16-3215","volume":"23","author":"S Jiao","year":"2017","unstructured":"Jiao, S. et al. PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression. Clin. Cancer Res. 23, 3711\u20133720 (2017).","journal-title":"Clin. Cancer Res."},{"key":"958_CR184","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1158\/0008-5472.CAN-18-1003","volume":"79","author":"J Shen","year":"2019","unstructured":"Shen, J. et al. PARPi triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCAness. Cancer Res. 79, 311\u2013319 (2019).","journal-title":"Cancer Res."},{"key":"958_CR185","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1001\/jamaoncol.2019.1029","volume":"5","author":"S Vinayak","year":"2019","unstructured":"Vinayak, S. et al. Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer. JAMA Oncol. 5, 1132\u20131140 (2019).","journal-title":"JAMA Oncol."},{"key":"958_CR186","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1001\/jamaoncol.2022.5228","volume":"9","author":"TA Yap","year":"2023","unstructured":"Yap, T. A. et al. Avelumab plus talazoparib in patients with advanced solid tumors. JAMA Oncol. 9, 29\u201339 (2023).","journal-title":"JAMA Oncol."},{"key":"958_CR187","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1001\/jamaoncol.2019.1048","volume":"5","author":"PA Konstantinopoulos","year":"2019","unstructured":"Konstantinopoulos, P. A. et al. Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma. JAMA Oncol. 5, 1141\u20131149 (2019).","journal-title":"JAMA Oncol."},{"key":"958_CR188","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/S1470-2045(20)30324-7","volume":"21","author":"SM Domchek","year":"2020","unstructured":"Domchek, S. M. et al. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1\/2, basket study. Lancet Oncol. 21, 1155\u20131164 (2020).","journal-title":"Lancet Oncol."},{"key":"958_CR189","doi-asserted-by":"publisher","first-page":"PO-085","DOI":"10.1158\/1557-3265.AACRAHNS23-PO-085","volume":"29","author":"AA Osman","year":"2023","unstructured":"Osman, A. A. et al. Inhibition of ATR as a therapeutic strategy to enhance immunotherapy in head and neck cancer. Clin. Cancer Res. 29, PO-085 (2023).","journal-title":"Clin. Cancer Res."},{"key":"958_CR190","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1158\/2159-8290.CD-20-0868","volume":"11","author":"TA Yap","year":"2021","unstructured":"Yap, T. A. et al. First-in-human trial of the oral ataxia telangiectasia and RAD3-related (ATR) inhibitor BAY 1895344 in patients with advanced solid tumors. Cancer Discov. 11, 80\u201391 (2021).","journal-title":"Cancer Discov."},{"key":"958_CR191","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-06705-3","volume":"15","author":"MI Shoulkamy","year":"2025","unstructured":"Shoulkamy, M. I., Mohammed, T. O., Ide, H. & Nakano, T. DNA\u2013protein cross-links emerge as major contributors to chemotherapeutic cytotoxicity at physiological equitoxic doses. Sci. Rep. 15, 23330 (2025).","journal-title":"Sci. Rep."},{"key":"958_CR192","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.immuni.2014.10.019","volume":"41","author":"L Deng","year":"2014","unstructured":"Deng, L. et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity 41, 843\u2013852 (2014). This study establishes that radiation therapy activates the cGAS\u2013STING pathway to induce type I interferons, which is essential for radiation\u2019s abscopal antitumour effects.","journal-title":"Immunity"},{"key":"958_CR193","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2024.110424","volume":"199","author":"SW Wang","year":"2024","unstructured":"Wang, S. W. et al. Mechanism of immune activation mediated by genomic instability and its implication in radiotherapy combined with immune checkpoint inhibitors. Radiother. Oncol. 199, 110424 (2024).","journal-title":"Radiother. Oncol."},{"key":"958_CR194","doi-asserted-by":"publisher","first-page":"6771","DOI":"10.1158\/1078-0432.CCR-17-0895","volume":"23","author":"M Scurr","year":"2017","unstructured":"Scurr, M. et al. Low-dose cyclophosphamide induces antitumor T-cell responses, which associate with survival in metastatic colorectal cancer. Clin. Cancer Res. 23, 6771\u20136780 (2017).","journal-title":"Clin. Cancer Res."},{"key":"958_CR195","doi-asserted-by":"publisher","first-page":"5458","DOI":"10.1158\/0008-5472.CAN-14-1258","volume":"74","author":"SJ Dovedi","year":"2014","unstructured":"Dovedi, S. J. et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res. 74, 5458\u20135468 (2014).","journal-title":"Cancer Res."},{"key":"958_CR196","doi-asserted-by":"publisher","first-page":"S604","DOI":"10.1016\/j.jtho.2025.09.1142","volume":"20","author":"S Lin","year":"2025","unstructured":"Lin, S., Xu, S., Ren, P. R., Zou, L. & Zhang, X. Chemoradiotherapy plus tislelizumab in advanced or metastatic NSCLC: a prospective, multicenter, phase II study. J. Thorac. Oncol. 20, S604 (2025).","journal-title":"J. Thorac. Oncol."},{"key":"958_CR197","volume":"6","author":"BC Cho","year":"2025","unstructured":"Cho, B. C. et al. Durvalumab with or without tremelimumab in combination with chemoradiotherapy in patients with limited-stage SCLC: results from the phase 1 CLOVER study. JTO Clin. Res. Rep. 6, 100884 (2025).","journal-title":"JTO Clin. Res. Rep."},{"key":"958_CR198","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","volume":"379","author":"SJ Antonia","year":"2018","unstructured":"Antonia, S. J. et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N. Engl. J. Med. 379, 2342\u20132350 (2018). This practice-changing phase III trial (PACIFIC) demonstrates that consolidation durvalumab after chemoradiation significantly improves survival in unresectable stage III NSCLC cancer.","journal-title":"N. Engl. J. Med."},{"key":"958_CR199","volume":"18","author":"Q Zhu","year":"2025","unstructured":"Zhu, Q. et al. Chemoradiotherapy combined with ICIs in the treatment of high PD-L1 expression-sensitive patients with non-small cell lung cancer. J. Radiat. Res. Appl. Sci. 18, 101318 (2025).","journal-title":"J. Radiat. Res. Appl. Sci."},{"key":"958_CR200","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S0140-6736(24)00317-9","volume":"403","author":"D Lorusso","year":"2024","unstructured":"Lorusso, D. et al. Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11\/GOG-3047\/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial. Lancet 403, 1341\u20131350 (2024).","journal-title":"Lancet"},{"key":"958_CR201","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ijrobp.2020.01.030","volume":"108","author":"SN Seyedin","year":"2020","unstructured":"Seyedin, S. N. et al. Combination therapy with radiation and PARP inhibition enhances responsiveness to anti-PD-1 therapy in colorectal tumor models. Int. J. Radiat. Oncol. Biol. Phys. 108, 81\u201392 (2020).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"958_CR202","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215852","volume":"545","author":"N Zhang","year":"2022","unstructured":"Zhang, N. et al. PARP inhibitor plus radiotherapy reshapes an inflamed tumor microenvironment that sensitizes small cell lung cancer to the anti-PD-1 immunotherapy. Cancer Lett. 545, 215852 (2022).","journal-title":"Cancer Lett."},{"key":"958_CR203","doi-asserted-by":"publisher","first-page":"e342","DOI":"10.1016\/j.cllc.2022.04.003","volume":"23","author":"SK Jabbour","year":"2022","unstructured":"Jabbour, S. K. et al. Rationale and design of the phase III KEYLYNK-012 study of pembrolizumab and concurrent chemoradiotherapy followed by pembrolizumab with or without olaparib for stage III non-small-cell lung cancer. Clin. Lung Cancer 23, e342\u2013e346 (2022).","journal-title":"Clin. Lung Cancer"},{"key":"958_CR204","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41577-023-00973-8","volume":"24","author":"LH Butterfield","year":"2024","unstructured":"Butterfield, L. H. & Najjar, Y. G. Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations. Nat. Rev. Immunol. 24, 399\u2013416 (2024).","journal-title":"Nat. Rev. Immunol."},{"key":"958_CR205","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1646568","volume":"16","author":"Y Hong","year":"2025","unstructured":"Hong, Y. et al. Immunotherapy combined with definitive chemoradiotherapy for locally advanced unresectable esophageal squamous cell carcinoma. Front. Immunol. 16, 1646568 (2025).","journal-title":"Front. Immunol."},{"key":"958_CR206","doi-asserted-by":"publisher","first-page":"6007","DOI":"10.1200\/JCO.2022.40.16_suppl.6007","volume":"40","author":"DA Clump","year":"2022","unstructured":"Clump, D. A. et al. A randomized phase II study evaluating concurrent or sequential fixed-dose immune therapy in combination with cisplatin and intensity-modulated radiotherapy in intermediate- or high-risk, previously untreated, locally advanced head and neck cancer (LA SCCHN). J. Clin. Oncol. 40, 6007 (2022).","journal-title":"J. Clin. Oncol."},{"key":"958_CR207","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1200\/JCO-24-01580","volume":"43","author":"DP Zandberg","year":"2025","unstructured":"Zandberg, D. P. et al. Randomized phase II study of concurrent versus sequential pembrolizumab in combination with chemoradiation in locally advanced head and neck cancer. J. Clin. Oncol. 43, 2572\u20132582 (2025).","journal-title":"J. Clin. Oncol."},{"key":"958_CR208","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49873-y","volume":"15","author":"I Telarovic","year":"2024","unstructured":"Telarovic, I. et al. Delayed tumor-draining lymph node irradiation preserves the efficacy of combined radiotherapy and immune checkpoint blockade in models of metastatic disease. Nat. Commun. 15, 5500 (2024).","journal-title":"Nat. Commun."},{"key":"958_CR209","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41392-025-02280-1","volume":"10","author":"M Tufail","year":"2025","unstructured":"Tufail, M., Jiang, C. H. & Li, N. Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches. Signal Transduct. Target. Ther. 10, 227 (2025).","journal-title":"Signal Transduct. Target. Ther."},{"key":"958_CR210","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1038\/s41588-023-01499-4","volume":"55","author":"PMK Westcott","year":"2023","unstructured":"Westcott, P. M. K. et al. Mismatch repair deficiency is not sufficient to elicit tumor immunogenicity. Nat. Genet. 55, 1686\u20131695 (2023).","journal-title":"Nat. Genet."},{"key":"958_CR211","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nature14410","volume":"521","author":"AM Patch","year":"2015","unstructured":"Patch, A. M. et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature 521, 489\u2013494 (2015).","journal-title":"Nature"},{"key":"958_CR212","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1158\/2159-8290.CD-18-0715","volume":"9","author":"KK Lin","year":"2019","unstructured":"Lin, K. K. et al. BRCA reversion mutations in circulating tumor DNA predict primary and acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma. Cancer Discov. 9, 210\u2013219 (2019).","journal-title":"Cancer Discov."},{"key":"958_CR213","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/nature14184","volume":"518","author":"R Ceccaldi","year":"2015","unstructured":"Ceccaldi, R. et al. Homologous-recombination-deficient tumours are dependent on Pol\u03b8-mediated repair. Nature 518, 258\u2013262 (2015). This discovery identifies Pol \u03b8 as a synthetic lethal target in HR-deficient cancers, opening a new therapeutic avenue for BRCA1\/2-mutant tumours.","journal-title":"Nature"},{"key":"958_CR214","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12272-9","volume":"10","author":"SJ Black","year":"2019","unstructured":"Black, S. J. et al. Molecular basis of microhomology-mediated end-joining by purified full-length Pol\u03b8. Nat. Commun. 10, 4423 (2019).","journal-title":"Nat. Commun."},{"key":"958_CR215","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.molcel.2020.12.037","volume":"81","author":"L Mohr","year":"2021","unstructured":"Mohr, L. et al. ER-directed TREX1 limits cGAS activation at micronuclei. Mol. Cell 81, 724\u2013738.e9 (2021).","journal-title":"Mol. Cell"},{"key":"958_CR216","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1158\/2326-6066.CIR-23-1093","volume":"12","author":"E Toufektchan","year":"2024","unstructured":"Toufektchan, E. et al. Intratumoral TREX1 induction promotes immune evasion by limiting type I IFN. Cancer Immunol. Res. 12, 673\u2013686 (2024).","journal-title":"Cancer Immunol. Res."},{"key":"958_CR217","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/s43018-020-0028-4","volume":"1","author":"JA Carozza","year":"2020","unstructured":"Carozza, J. A. et al. Extracellular cGAMP is a cancer cell-produced immunotransmitter involved in radiation-induced anti-cancer immunity. Nat. Cancer 1, 184\u2013196 (2020).","journal-title":"Nat. Cancer"},{"key":"958_CR218","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/nchembio.1661","volume":"10","author":"L Li","year":"2014","unstructured":"Li, L. et al. Hydrolysis of 2\u20323\u2032-cGAMP by ENPP1 and design of nonhydrolyzable analogs. Nat. Chem. Biol. 10, 1043\u20131048 (2014).","journal-title":"Nat. Chem. Biol."},{"key":"958_CR219","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1158\/2159-8290.CD-20-0387","volume":"11","author":"J Li","year":"2021","unstructured":"Li, J. et al. Metastasis and immune evasion from extracellular cGAMP hydrolysis. Cancer Discov. 11, 1212\u20131227 (2021).","journal-title":"Cancer Discov."},{"key":"958_CR220","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2313693120","volume":"120","author":"S Wang","year":"2023","unstructured":"Wang, S. et al. ENPP1 is an innate immune checkpoint of the anticancer cGAMP\u2013STING pathway in breast cancer. Proc. Natl Acad. Sci. USA 120, e2313693120 (2023).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"958_CR221","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/j.ccell.2021.06.018","volume":"39","author":"JM Gozgit","year":"2021","unstructured":"Gozgit, J. M. et al. PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity. Cancer Cell 39, 1214\u20131226.e10 (2021).","journal-title":"Cancer Cell"},{"key":"958_CR222","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.cotox.2017.01.013","volume":"2","author":"J Matthews","year":"2017","unstructured":"Matthews, J. AHR toxicity and signaling: role of TIPARP and ADP-ribosylation. Curr. Opin. Toxicol. 2, 50\u201357 (2017).","journal-title":"Curr. Opin. Toxicol."},{"key":"958_CR223","doi-asserted-by":"publisher","first-page":"djw199","DOI":"10.1093\/jnci\/djw199","volume":"109","author":"EE Parkes","year":"2017","unstructured":"Parkes, E. E. et al. Activation of STING-dependent innate immune signaling by S-phase-specific DNA damage in breast cancer. J. Natl Cancer Inst. 109, djw199 (2017).","journal-title":"J. Natl Cancer Inst."},{"key":"958_CR224","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02156-y","volume":"23","author":"A Zhang","year":"2024","unstructured":"Zhang, A. et al. Regulatory T cells in immune checkpoint blockade antitumor therapy. Mol. Cancer 23, 251 (2024).","journal-title":"Mol. Cancer"},{"key":"958_CR225","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/j.trecan.2022.06.008","volume":"8","author":"F Shan","year":"2022","unstructured":"Shan, F., Somasundaram, A., Bruno, T. C., Workman, C. J. & Vignali, D. A. A. Therapeutic targeting of regulatory T cells in cancer. Trends Cancer 8, 944\u2013961 (2022).","journal-title":"Trends Cancer"},{"key":"958_CR226","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1093\/annonc\/mdz135","volume":"30","author":"UA Matulonis","year":"2019","unstructured":"Matulonis, U. A. et al. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. Ann. Oncol. 30, 1080\u20131087 (2019).","journal-title":"Ann. Oncol."},{"key":"958_CR227","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1038\/s41586-023-06464-z","volume":"620","author":"J Li","year":"2023","unstructured":"Li, J. et al. Non-cell-autonomous cancer progression from chromosomal instability. Nature 620, 1080\u20131088 (2023).","journal-title":"Nature"},{"key":"958_CR228","doi-asserted-by":"publisher","DOI":"10.1126\/science.adf1329","volume":"384","author":"D Mathew","year":"2024","unstructured":"Mathew, D. et al. Combined JAK inhibition and PD-1 immunotherapy for non-small cell lung cancer patients. Science 384, eadf1329 (2024).","journal-title":"Science"},{"key":"958_CR229","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111647","volume":"41","author":"W Chen","year":"2022","unstructured":"Chen, W. et al. Chronic type I interferon signaling promotes lipid-peroxidation-driven terminal CD8+ T cell exhaustion and curtails anti-PD-1 efficacy. Cell Rep. 41, 111647 (2022).","journal-title":"Cell Rep."},{"key":"958_CR230","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1038\/s41590-022-01152-y","volume":"23","author":"TS Sumida","year":"2022","unstructured":"Sumida, T. S. et al. Type I interferon transcriptional network regulates expression of coinhibitory receptors in human T cells. Nat. Immunol. 23, 632\u2013642 (2022).","journal-title":"Nat. Immunol."},{"key":"958_CR231","doi-asserted-by":"publisher","unstructured":"Park, S. J., Bencsics, M., Veres, D. S. & Horv\u00e1th, E. M. The novel combination therapy of PARP inhibitors and immune checkpoint inhibitors for ovarian cancer: a single-arm meta-analysis and systematic review. Heliyon https:\/\/doi.org\/10.1016\/j.heliyon.2026.e44789 (2026).","DOI":"10.1016\/j.heliyon.2026.e44789"},{"key":"958_CR232","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1158\/2767-9764.CRC-22-0140","volume":"3","author":"E Rosenbaum","year":"2023","unstructured":"Rosenbaum, E. et al. Immune-related adverse events after immune checkpoint blockade-based therapy are associated with improved survival in advanced sarcomas. Cancer Res. Commun. 3, 2118\u20132125 (2023).","journal-title":"Cancer Res. Commun."},{"key":"958_CR233","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s10585-024-10307-0","volume":"41","author":"Q Zheng","year":"2024","unstructured":"Zheng, Q., Zhou, T. & Ding, W. Efficacy and safety of PARPis combined with an ICIs for advanced or metastatic triple-negative breast cancer: a single-arm meta-analysis. Clin. Exp. Metastasis 41, 843\u2013850 (2024).","journal-title":"Clin. Exp. Metastasis"},{"key":"958_CR234","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/s41416-023-02349-0","volume":"129","author":"M Friedlander","year":"2023","unstructured":"Friedlander, M. et al. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trial. Br. J. Cancer 129, 797\u2013810 (2023).","journal-title":"Br. J. Cancer"},{"key":"958_CR235","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1200\/JCO.2017.76.9901","volume":"36","author":"MJ Overman","year":"2018","unstructured":"Overman, M. J. et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient\/microsatellite instability-high metastatic colorectal cancer. J. Clin. Oncol. 36, 773\u2013779 (2018).","journal-title":"J. Clin. Oncol."},{"key":"958_CR236","doi-asserted-by":"publisher","first-page":"114875","DOI":"10.1016\/j.celrep.2024.114875","volume":"43","author":"S Keshari","year":"2024","unstructured":"Keshari, S. et al. Comparing neoantigen cancer vaccines and immune checkpoint therapy unveils an effective vaccine and anti-TREM2 macrophage-targeting dual therapy. Cell Rep. 43, 114875 (2024).","journal-title":"Cell Rep."},{"key":"958_CR237","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s10238-024-01436-7","volume":"24","author":"D-W Wu","year":"2024","unstructured":"Wu, D.-W. et al. Personalized neoantigen cancer vaccines: current progression, challenges and a bright future. Clin. Exp. Med. 24, 229 (2024).","journal-title":"Clin. Exp. Med."},{"key":"958_CR238","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","volume":"6","author":"M Ramos-Casals","year":"2020","unstructured":"Ramos-Casals, M. et al. Immune-related adverse events of checkpoint inhibitors. Nat. Rev. Dis. Primers 6, 38 (2020).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"958_CR239","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.ymthe.2022.08.025","volume":"31","author":"M El-Hajjar","year":"2023","unstructured":"El-Hajjar, M. et al. Inducing mismatch repair deficiency sensitizes immune-cold neuroblastoma to anti-CTLA4 and generates broad anti-tumor immune memory. Mol. Ther. 31, 535\u2013551 (2023).","journal-title":"Mol. Ther."},{"key":"958_CR240","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30568-1","volume":"13","author":"Q Wang","year":"2022","unstructured":"Wang, Q. et al. STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer. Nat. Commun. 13, 3022 (2022).","journal-title":"Nat. Commun."},{"key":"958_CR241","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.alit.2022.01.001","volume":"71","author":"N Okiyama","year":"2022","unstructured":"Okiyama, N. & Tanaka, R. Immune-related adverse events in various organs caused by immune checkpoint inhibitors. Allergology Int. 71, 169\u2013178 (2022).","journal-title":"Allergology Int."},{"key":"958_CR242","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1158\/1078-0432.CCR-24-1660","volume":"31","author":"JC McVey","year":"2025","unstructured":"McVey, J. C. & Beatty, G. L. Facts and hopes of CD40 agonists in cancer immunotherapy. Clin. Cancer Res. 31, 2079\u20132087 (2025).","journal-title":"Clin. Cancer Res."},{"key":"958_CR243","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02380-0","volume":"24","author":"Q Wang","year":"2025","unstructured":"Wang, Q., Yu, Y., Zhuang, J., Liu, R. & Sun, C. Demystifying the cGAS\u2013STING pathway: precision regulation in the tumor immune microenvironment. Mol. Cancer 24, 178 (2025).","journal-title":"Mol. Cancer"},{"key":"958_CR244","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1172\/JCI123319","volume":"129","author":"RM Chabanon","year":"2019","unstructured":"Chabanon, R. M. et al. PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer. J. Clin. Invest. 129, 1211\u20131228 (2019).","journal-title":"J. Clin. Invest."},{"key":"958_CR245","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.annonc.2022.05.519","volume":"33","author":"M Maio","year":"2022","unstructured":"Maio, M. et al. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study. Ann. Oncol. 33, 929\u2013938 (2022).","journal-title":"Ann. Oncol."},{"key":"958_CR246","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1172\/JCI84940","volume":"126","author":"JM Mehnert","year":"2016","unstructured":"Mehnert, J. M. et al. Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer. J. Clin. Invest. 126, 2334\u20132340 (2016). This pivotal paper shows that POLE proofreading domain mutations cause an ultramutator phenotype and robust immune infiltration, explaining the striking sensitivity of POLE-mutant cancers to PD1 blockade.","journal-title":"J. Clin. Invest."},{"key":"958_CR247","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41591-018-0040-8","volume":"24","author":"N Zacharakis","year":"2018","unstructured":"Zacharakis, N. et al. Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. Nat. Med. 24, 724\u2013730 (2018).","journal-title":"Nat. Med."},{"key":"958_CR248","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1038\/s41568-024-00714-6","volume":"24","author":"MA Harris","year":"2024","unstructured":"Harris, M. A. et al. Towards targeting the breast cancer immune microenvironment. Nat. Rev. Cancer 24, 554\u2013577 (2024).","journal-title":"Nat. Rev. Cancer"},{"key":"958_CR249","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","volume":"51","author":"RM Samstein","year":"2019","unstructured":"Samstein, R. M. et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat. Genet. 51, 202\u2013206 (2019).","journal-title":"Nat. Genet."},{"key":"958_CR250","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1158\/0008-5472.CAN-24-0943","volume":"84","author":"S Zhang","year":"2024","unstructured":"Zhang, S. et al. Integration of clinical trial spatial multiomics analysis and virtual clinical trials enables immunotherapy response prediction and biomarker discovery. Cancer Res. 84, 2734\u20132748 (2024).","journal-title":"Cancer Res."},{"key":"958_CR251","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1001\/jamaoncol.2022.4933","volume":"9","author":"M Rakaee","year":"2023","unstructured":"Rakaee, M. et al. Association of machine learning-based assessment of tumor-infiltrating lymphocytes on standard histologic images with outcomes of immunotherapy in patients with NSCLC. JAMA Oncol. 9, 51\u201360 (2023).","journal-title":"JAMA Oncol."},{"key":"958_CR252","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"958_CR253","doi-asserted-by":"publisher","first-page":"4268","DOI":"10.1158\/1078-0432.CCR-20-0056","volume":"26","author":"EJ Lampert","year":"2020","unstructured":"Lampert, E. J. et al. Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase II study. Clin. Cancer Res. 26, 4268\u20134279 (2020).","journal-title":"Clin. Cancer Res."},{"key":"958_CR254","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/S1470-2045(22)00369-2","volume":"23","author":"KA Reiss","year":"2022","unstructured":"Reiss, K. A. et al. Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b\/2 trial. Lancet Oncol. 23, 1009\u20131020 (2022).","journal-title":"Lancet Oncol."},{"key":"958_CR255","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41435-024-00280-9","volume":"25","author":"Y Chen","year":"2024","unstructured":"Chen, Y., Fan, X., Lu, R., Zeng, S. & Gan, P. PARP inhibitor and immune checkpoint inhibitor have synergism efficacy in gallbladder cancer. Genes Immun. 25, 307\u2013316 (2024).","journal-title":"Genes Immun."},{"key":"958_CR256","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1158\/1078-0432.CCR-23-2249","volume":"30","author":"Y Drew","year":"2024","unstructured":"Drew, Y. et al. Olaparib plus durvalumab, with or without bevacizumab, as treatment in PARP inhibitor-na\u00efve platinum-sensitive relapsed ovarian cancer: a phase II multi-cohort study. Clin. Cancer Res. 30, 50\u201362 (2024).","journal-title":"Clin. Cancer Res."},{"key":"958_CR257","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1042\/BST20220681","volume":"51","author":"NJ Curtin","year":"2023","unstructured":"Curtin, N. J. Targeting the DNA damage response for cancer therapy. Biochem. Soc. Trans. 51, 207\u2013221 (2023).","journal-title":"Biochem. Soc. Trans."},{"key":"958_CR258","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ijrobp.2020.04.034","volume":"108","author":"SC Formenti","year":"2020","unstructured":"Formenti, S. C. & Demaria, S. Future of radiation and immunotherapy. Int. J. Radiat. Oncol. Biol. Phys. 108, 3\u20135 (2020).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"958_CR259","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.165615","volume":"8","author":"FP Vendetti","year":"2023","unstructured":"Vendetti, F. P. et al. The schedule of ATR inhibitor AZD6738 can potentiate or abolish antitumor immune responses to radiotherapy. JCI Insight 8, e165615 (2023).","journal-title":"JCI Insight"},{"key":"958_CR260","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT05118724 (2025)."},{"key":"958_CR261","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT05371197 (2022)."},{"key":"958_CR262","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT06333314 (2025)."},{"key":"958_CR263","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT06428487 (2026)."},{"key":"958_CR264","doi-asserted-by":"publisher","DOI":"10.1200\/PO-25-00602","volume":"9","author":"O Kuznetsova","year":"2025","unstructured":"Kuznetsova, O. et al. Neoadjuvant immunotherapy with prolgolimab in patients with locally advanced microsatellite instability\/defective mismatch repair colorectal cancer. JCO Precis. Oncol. 9, e2500602 (2025).","journal-title":"JCO Precis. Oncol."},{"key":"958_CR265","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT04795661 (2026)."},{"key":"958_CR266","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1200\/JCO-25-02169","volume":"44","author":"C de la Fouchardi\u00e8re","year":"2026","unstructured":"de la Fouchardi\u00e8re, C. et al. Efficacy of perioperative pembrolizumab in mismatch repair deficient\/microsatellite unstable localized colorectal cancers: results of the phase II trial IMHOTEP. J. Clin. Oncol. 44, 1520\u20131528 (2026).","journal-title":"J. Clin. Oncol."},{"key":"958_CR267","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2025.7044","volume":"23","author":"KA Klute","year":"2025","unstructured":"Klute, K. A. & Shah, M. A. Evolving therapeutics for resectable esophageal adenocarcinoma. J. Natl Compr. Canc Netw. 23, e257044 (2025).","journal-title":"J. Natl Compr. Canc Netw."},{"key":"958_CR268","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT01876511 (2020)."},{"key":"958_CR269","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT04098068 (2025)."},{"key":"958_CR270","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT02332668 (2026)."},{"key":"958_CR271","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S1470-2045(19)30671-0","volume":"21","author":"B Geoerger","year":"2020","unstructured":"Geoerger, B. et al. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1\u20132 trial. Lancet Oncol. 21, 121\u2013133 (2020).","journal-title":"Lancet Oncol."},{"key":"958_CR272","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT02563002 (2024)."},{"key":"958_CR273","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S1470-2045(21)00064-4","volume":"22","author":"T Andre","year":"2021","unstructured":"Andre, T. et al. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial. Lancet Oncol. 22, 665\u2013677 (2021).","journal-title":"Lancet Oncol."},{"key":"958_CR274","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/S1470-2045(22)00197-8","volume":"23","author":"LA Diaz Jr","year":"2022","unstructured":"Diaz, L. A. Jr et al. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. Lancet Oncol. 23, 659\u2013670 (2022).","journal-title":"Lancet Oncol."},{"key":"958_CR275","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1111\/cas.15650","volume":"114","author":"T Yoshino","year":"2023","unstructured":"Yoshino, T. et al. Pembrolizumab in Asian patients with microsatellite-instability-high\/mismatch-repair-deficient colorectal cancer. Cancer Sci. 114, 1026\u20131036 (2023).","journal-title":"Cancer Sci."},{"key":"958_CR276","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT05994456 (2023)."},{"key":"958_CR277","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT05669092 (2022)."},{"key":"958_CR278","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-11829-2","volume":"24","author":"CY Huang","year":"2024","unstructured":"Huang, C. Y. et al. Anus preservation in low rectal adenocarcinoma based on MMR\/MSI status (APRAM): a study protocol for a randomised, controlled, open-label, multicentre phase III trial. BMC Cancer 24, 57 (2024).","journal-title":"BMC Cancer"},{"key":"958_CR279","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT06116136 (2026)."},{"key":"958_CR280","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT03810339 (2026)."},{"key":"958_CR281","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT03436563 (2024)."},{"key":"958_CR282","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1158\/1078-0432.CCR-20-2403","volume":"27","author":"JS Morris","year":"2021","unstructured":"Morris, J. S. et al. Development and validation of a gene signature classifier for consensus molecular subtyping of colorectal carcinoma in a CLIA-certified setting. Clin. Cancer Res. 27, 120\u2013130 (2021).","journal-title":"Clin. Cancer Res."},{"key":"958_CR283","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT06152523 (2026)."},{"key":"958_CR284","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT06346197 (2026)."},{"key":"958_CR285","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT05310643 (2025)."},{"key":"958_CR286","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT04730544 (2025)."},{"key":"958_CR287","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT04006262 (2025)."},{"key":"958_CR288","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1200\/JCO.22.00686","volume":"41","author":"T Andr\u00e9","year":"2023","unstructured":"Andr\u00e9, T. et al. Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair\/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: the GERCOR NEONIPIGA phase II study. J. Clin. Oncol. 41, 255\u2013265 (2023).","journal-title":"J. Clin. Oncol."},{"key":"958_CR289","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT03104439 (2026)."},{"key":"958_CR290","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1038\/s43018-021-00269-7","volume":"2","author":"AR Parikh","year":"2021","unstructured":"Parikh, A. R. et al. Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial. Nat. Cancer 2, 1124\u20131135 (2021).","journal-title":"Nat. Cancer"},{"key":"958_CR291","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT03607890 (2026)."},{"key":"958_CR292","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT03767348 (2026)."},{"key":"958_CR293","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/s40425-019-0682-1","volume":"7","author":"S Thomas","year":"2019","unstructured":"Thomas, S. et al. Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1. J. Immunother. Cancer 7, 214 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"958_CR294","doi-asserted-by":"publisher","first-page":"3589","DOI":"10.1200\/JCO-25-01346","volume":"43","author":"MK Wong","year":"2025","unstructured":"Wong, M. K. et al. RP1 combined with nivolumab in advanced anti-PD-1-failed melanoma (IGNYTE). J. Clin. Oncol. 43, 3589\u20133599 (2025).","journal-title":"J. Clin. Oncol."},{"key":"958_CR295","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT03827044 (2022)."},{"key":"958_CR296","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2019-000638","volume":"5","author":"D Lau","year":"2020","unstructured":"Lau, D. et al. Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised study. ESMO Open\u00a05, e000638 (2020).","journal-title":"ESMO Open"},{"key":"958_CR297","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT05483400 (2025)."},{"key":"958_CR298","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT05836584 (2026)."},{"key":"958_CR299","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT02982694 (2025)."},{"key":"958_CR300","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT04715633 (2024)."},{"key":"958_CR301","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/S1470-2045(24)00203-1","volume":"25","author":"JH Yu","year":"2024","unstructured":"Yu, J. H. et al. Neoadjuvant camrelizumab plus apatinib for locally advanced microsatellite instability-high or mismatch repair-deficient colorectal cancer (NEOCAP): a single-arm, open-label, phase 2 study. Lancet Oncol. 25, 843\u2013852 (2024).","journal-title":"Lancet Oncol."},{"key":"958_CR302","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT06516289 (2024)."},{"key":"958_CR303","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT06006923 (2026)."},{"key":"958_CR304","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT05838768 (2026)."},{"key":"958_CR305","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT05035381 (2021)."},{"key":"958_CR306","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT02060188 (2025)."},{"key":"958_CR307","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008689","volume":"12","author":"MJ Overman","year":"2024","unstructured":"Overman, M. J. et al. Nivolumab plus relatlimab in patients with previously treated microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study. J. Immunother. Cancer 12, e008689 (2024).","journal-title":"J. Immunother. Cancer"},{"key":"958_CR308","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","volume":"18","author":"MJ Overman","year":"2017","unstructured":"Overman, M. J. et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 18, 1182\u20131191 (2017).","journal-title":"Lancet Oncol."},{"key":"958_CR309","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1200\/JCO.21.01015","volume":"40","author":"HJ Lenz","year":"2022","unstructured":"Lenz, H. J. et al. First-line nivolumab plus low-dose ipilimumab for microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study. J. Clin. Oncol. 40, 161\u2013170 (2022).","journal-title":"J. Clin. Oncol."},{"key":"958_CR310","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT06365970 (2025)."},{"key":"958_CR311","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT04584255 (2026)."},{"key":"958_CR312","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT04673448 (2026)."},{"key":"958_CR313","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT05485766 (2025)."},{"key":"958_CR314","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT04681469 (2022)."},{"key":"958_CR315","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT05700721 (2026)."},{"key":"958_CR316","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT05526989 (2025)."},{"key":"958_CR317","doi-asserted-by":"publisher","first-page":"3619","DOI":"10.1080\/14796694.2025.2577632","volume":"21","author":"F Hatoum","year":"2025","unstructured":"Hatoum, F. et al. Phase 2 study of dostarlimab plus niraparib in stage III\u2013IV recurrent or refractory penile squamous cell carcinoma. Future Oncol. 21, 3619\u20133627 (2025).","journal-title":"Future Oncol."},{"key":"958_CR318","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT04068753 (2026)."},{"key":"958_CR319","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT04940637 (2023)."},{"key":"958_CR320","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT04983745 (2023)."},{"key":"958_CR321","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT05366166 (2026)."},{"key":"958_CR322","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT04548752 (2026)."},{"key":"958_CR323","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT06160843 (2025)."},{"key":"958_CR324","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT06116578 (2025)."},{"key":"958_CR325","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT04825990 (2026)."},{"key":"958_CR326","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT05524935 (2026)."},{"key":"958_CR327","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT05093231 (2026)."},{"key":"958_CR328","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT05222971 (2025)."},{"key":"958_CR329","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ejca.2019.07.022","volume":"120","author":"H Chae","year":"2019","unstructured":"Chae, H. et al. Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene mutations as a predictive biomarker. Eur. J. Cancer 120, 31\u201339 (2019).","journal-title":"Eur. J. Cancer"},{"key":"958_CR330","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1903387","volume":"381","author":"T Golan","year":"2019","unstructured":"Golan, T. et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N. Engl. J. Med. 381, 317\u2013327 (2019).","journal-title":"N. Engl. J. Med."},{"key":"958_CR331","doi-asserted-by":"publisher","first-page":"901","DOI":"10.4143\/crt.2018.326","volume":"51","author":"J Hyung","year":"2019","unstructured":"Hyung, J. et al. Clinical benefit of maintenance therapy for advanced biliary tract cancer patients showing no progression after first-line gemcitabine plus cisplatin. Cancer Res. Treat. 51, 901\u2013909 (2019).","journal-title":"Cancer Res. Treat."},{"key":"958_CR332","doi-asserted-by":"publisher","first-page":"594","DOI":"10.4143\/crt.2019.493","volume":"52","author":"J Kang","year":"2020","unstructured":"Kang, J. et al. Efficacy and safety of pembrolizumab in patients with refractory advanced biliary tract cancer: tumor proportion score as a potential biomarker for response. Cancer Res. Treat. 52, 594\u2013603 (2020).","journal-title":"Cancer Res. Treat."},{"key":"958_CR333","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1200\/JCO.2017.75.7740","volume":"36","author":"MY Teo","year":"2018","unstructured":"Teo, M. Y. et al. Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1\/PD-L1 blockade in advanced urothelial cancers. J. Clin. Oncol. 36, 1685\u20131694 (2018).","journal-title":"J. Clin. Oncol."},{"key":"958_CR334","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle, J. et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N. Engl. J. Med. 362, 1273\u20131281 (2010).","journal-title":"N. Engl. J. Med."},{"key":"958_CR335","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT04644289 (2025)."},{"key":"958_CR336","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT03991832 (2026)."},{"key":"958_CR337","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT06441747 (2026)."},{"key":"958_CR338","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT05656131 (2026)."},{"key":"958_CR339","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT04978012 (2022)."},{"key":"958_CR340","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1200\/JCO.20.02712","volume":"39","author":"FH Wang","year":"2021","unstructured":"Wang, F. H. et al. Efficacy, safety, and correlative biomarkers of toripalimab in previously treated recurrent or metastatic nasopharyngeal carcinoma: a phase II clinical trial (POLARIS-02). J. Clin. Oncol. 39, 704\u2013712 (2021).","journal-title":"J. Clin. Oncol."},{"key":"958_CR341","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1200\/JCO.2017.77.0388","volume":"36","author":"BBY Ma","year":"2018","unstructured":"Ma, B. B. Y. et al. Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: an international, multicenter study of the Mayo Clinic Phase 2 Consortium (NCI-9742). J. Clin. Oncol. 36, 1412\u20131418 (2018).","journal-title":"J. Clin. Oncol."},{"key":"958_CR342","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1002\/path.5018","volume":"244","author":"RW Lung","year":"2018","unstructured":"Lung, R. W. et al. EBV-encoded miRNAs target ATM-mediated response in nasopharyngeal carcinoma. J. Pathol. 244, 394\u2013407 (2018).","journal-title":"J. Pathol."},{"key":"958_CR343","doi-asserted-by":"publisher","first-page":"3060","DOI":"10.3389\/fimmu.2018.03060","volume":"9","author":"M Tatfi","year":"2018","unstructured":"Tatfi, M., Hermine, O. & Suarez, F. Epstein\u2013Barr virus (EBV)-related lymphoproliferative disorders in ataxia telangiectasia: does ATM rRegulate EBV life cycle? Front. Immunol. 9, 3060 (2018).","journal-title":"Front. Immunol."},{"key":"958_CR344","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT06413992 (2024)."},{"key":"958_CR345","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT04678362 (2025)."},{"key":"958_CR346","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-10216-z","volume":"22","author":"E Coquan","year":"2022","unstructured":"Coquan, E. et al. TALASUR trial: a single arm phase II trial assessing efficacy and safety of TALazoparib and Avelumab as maintenance therapy in platinum-Sensitive metastatic or locally advanced URothelial carcinoma. BMC Cancer 22, 1213 (2022).","journal-title":"BMC Cancer"},{"key":"958_CR347","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT04985721 (2023)."},{"key":"958_CR348","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT06518564 (2026)."},{"key":"958_CR349","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT05396833 (2026)."},{"key":"958_CR350","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT04065269 (2026)."},{"key":"958_CR351","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1097\/PPO.0000000000000561","volume":"27","author":"G Smith","year":"2021","unstructured":"Smith, G., Alholm, Z., Coleman, R. L. & Monk, B. J. DNA damage repair inhibitors\u2014combination therapies. Cancer J. 27, 501\u2013505 (2021).","journal-title":"Cancer J."},{"key":"958_CR352","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT03682289 (2026)."},{"key":"958_CR353","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1158\/1078-0432.CCR-25-4043","volume":"32","author":"X Zhu","year":"2026","unstructured":"Zhu, X. et al. Efficacy of the ATR inhibitor ceralasertib in patients with ARID1A-deficient gynecologic and other solid tumor malignancies. Clin. Cancer Res. 32, 1632\u20131640 (2026).","journal-title":"Clin. Cancer Res."},{"key":"958_CR354","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT05941897 (2026)."},{"key":"958_CR355","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT05450692 (2026)."},{"key":"958_CR356","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT05882734 (2026)."},{"key":"958_CR357","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT06732401 (2026)."},{"key":"958_CR358","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT05787587 (2026)."},{"key":"958_CR359","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT04837209 (2026)."},{"key":"958_CR360","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT05568550 (2026)."},{"key":"958_CR361","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT04683679 (2026)."},{"key":"958_CR362","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT04711824 (2025)."},{"key":"958_CR363","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT05411094 (2026)."},{"key":"958_CR364","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT06074692 (2023)."},{"key":"958_CR365","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT05526924 (2026)."}],"container-title":["Nature Reviews Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41568-026-00958-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41568-026-00958-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41568-026-00958-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T12:07:55Z","timestamp":1787573275000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41568-026-00958-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":365,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["958"],"URL":"https:\/\/doi.org\/10.1038\/s41568-026-00958-4","relation":{},"ISSN":["1474-175X","1474-1768"],"issn-type":[{"value":"1474-175X","type":"print"},{"value":"1474-1768","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]},"assertion":[{"value":"25 June 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no competing interests to declare.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}